Małgorzata Szczygieł

Dr. Małgorzata Szczygieł

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
MKMartyna Krzykawska-Serda
Martyna Krzykawska-Serda
Janusz DabrowskiJanusz Dabrowski
Janusz Dabrowski
LALuís G. Arnaut
Luís G. Arnaut
MSMałgorzata Szczygieł
Małgorzata Szczygieł
KUKrystyna Urbanska
Krystyna Urbanska
MEMartyna Elas
Martyna Elas

8 July 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMałgorzata Szczygieł
Małgorzata Szczygieł
KUKrystyna Urbanska
Krystyna Urbanska
PJPatrycja Jurecka
Patrycja Jurecka
Iwona StawoskaIwona Stawoska
Iwona Stawoska
GSGrażyna Stochel
Grażyna Stochel
LFLeszek Fiedor
Leszek Fiedor

Verified
Journal Article
Open access
PDF file
MŚMartyna Śniegocka
Martyna Śniegocka
EPEwa Podgorska
Ewa Podgorska
Przemysław Mieszko PłonkaPrzemysław Mieszko Płonka
Przemysław Mieszko Płonka
MEMartyna Elas
Martyna Elas
Bożena Romanowska-DixonBożena Romanowska-Dixon
Bożena Romanowska-Dixon
KUKrystyna Urbanska
Krystyna Urbanska
The focus of the present review is to investigate the role of melanin in the radioprotection of melanoma and attempts to sensitize tumors to radiation by inhibiting melanogenesis. Early studies showed radical scavenging, oxygen consumption and adsorption as mechanisms of melanin radioprotection. Experimental models of melanoma in hamsters and in gerbils are described as well as their use in biochemical and radiobiological studies, including a spontaneously metastasizing ocular model. Some results from in vitro studies on the inhibition of melanogenesis are presented as well as radio-chelation therapy in experimental and clinical settings. In contrast to cutaneous melanoma, uveal melanoma is very successfully treated with radiation, both using photon and proton beams. We point out that the presence or lack of melanin pigmentation should be considered, when choosing therapeutic options, and that both the experimental and clinical data suggest that melanin could be a target for radiosensitizing melanoma cells to increase efficacy of radiotherapy against melanoma.

11 September 2015 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
JSJakub Staron
Jakub Staron
BBBożena Boron
Bożena Boron
Dariusz KarczDariusz Karcz
Dariusz Karcz
MSMałgorzata Szczygieł
Małgorzata Szczygieł
LFLeszek Fiedor
Leszek Fiedor
Since photodynamic therapy emerged as a promising cancer treatment, the development of photosensitizers has gained great interest. In this context, the photosynthetic pigments, chlorophylls and bacteriochlorophylls, as excellent natural photosensitizers, attracted much attention. In effect, several (bacterio) chlorophyll-based phototherapeutic agents have been developed and (or are about to) enter the clinics. The aim of this review article is to give a survey of the advances in the synthetic chemistry of these pigments which have been made over the last decade, and which are pertinent to the application of their derivatives as photosensitizers for photodynamic therapy (PDT). The review focuses on the synthetic strategies undertaken to obtain novel derivatives of (bacterio)chlorophylls with both enhanced photosensitizing and tumorlocalizing properties, and also improved photo- and chemical stability. These include modifications of the C- 17-ester moiety, the isocyclic ring, the central binding pocket, and the derivatization of peripheral functionalities at the C-3 and C-7 positions with carbohydrate-, peptide-, and nanoparticle moieties or other residues. The effects of these modifications on essential features of the pigments are discussed, such as the efficiency of reactive oxygen species generation, photostability, phototoxicity and interactions with living organisms. The review is divided into several sections. In the first part, the principles of PDT and photosensitizer action are briefly described. Then the relevant photophysical features of (bacterio)chlorophylls and earlier approaches to their modification are summarized. Next, a more detailed overview of the progress in synthetic methods is given, followed by a discussion of the effects of these modifications on the photophysics of the pigments and on their biological activity.

11 January 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MLMarcin Tomasz Luty
Marcin Tomasz Luty
KPKatarzyna Piwowarczyk
Katarzyna Piwowarczyk
ALAnna Labedz-Maslowska
Anna Labedz-Maslowska
TWTomasz Wróbel
Tomasz Wróbel
MSMałgorzata Szczygieł
Małgorzata Szczygieł
Jarosław CzyżJarosław Czyż
Jarosław Czyż
Metronomic agents reduce the effective doses and adverse effects of cytostatics in cancer chemotherapy. Therefore, they can enhance the treatment efficiency of drug-resistant cancers. Cytostatic and anti-angiogenic effects of fenofibrate (FF) suggest that it can be used for the metronomic chemotherapy of drug-resistant prostate tumors. To estimate the effect of FF on the drug-resistance of prostate cancer cells, we compared the reactions of naïve and drug-resistant cells to the combined treatment with docetaxel (DCX)/mitoxantrone (MTX) and FF. FF sensitized drug-resistant DU145 and PC3 cells to DCX and MTX, as illustrated by their reduced viability and invasive potential observed in the presence of DCX/MTX and FF. The synergy of the cytostatic activities of both agents was accompanied by the inactivation of P-gp-dependent efflux, dysfunction of the microtubular system, and induction of polyploidy in DCX-resistant cells. Chemical inhibition of PPARα- and reactive oxygen species (ROS)-dependent pathways by GW6471 and N-acetyl-L-cysteine, respectively, had no effect on cell sensitivity to combined DCX/FF treatment. Instead, we observed the signs of adenosine triphosphate (ATP) deficit and autophagy in DCX/FF-treated drug-resistant cells. Furthermore, the cells that had been permanently propagated under DCX- and DCX/FF-induced stress did not acquire DCX/FF-resistance. Instead, relatively slow proliferation of DCX-resistant cells was efficiently inhibited by FF. Collectively, our observations show that FF reduces the effective doses of DCX by interfering with the drug resistance and energy metabolism of prostate cancer cells. Concomitantly, it impairs the chemotherapy-induced microevolution and expansion of DCX/FF-resistant cells. Therefore, FF can be applied as a metronomic agent to enhance the efficiency of palliative chemotherapy of prostate cancer.

18 July 2014 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
MSMilena Julia Szafraniec
Milena Julia Szafraniec
MSMałgorzata Szczygieł
Małgorzata Szczygieł
KUKrystyna Urbanska
Krystyna Urbanska
LFLeszek Fiedor
Leszek Fiedor
The xenobiotic transporters are among the most important constituents of detoxification system in living organisms. Breast cancer resistance protein (BCRP/ABCG2) is one of the major transporters involved in the efflux of xenobiotics. To understand its role in chemotherapeutic and multidrug resistance, it is crucial to establish the determinants of its substrate specificity, which obviously is of high relevance for successful therapy of many diseases. This article summarizes the current knowledge about the substrate preferences of BCRP. We overview the factors which determine its activity, inhibition and substrate recognition, focusing on the structural features of the transporter. BCRP substrate specificity is quite low as it interacts with a spectrum of substances with only a few common features: hydrophobic and aromatic regions, possibly a flat conformation and the metal ion-, oxygen- and nitrogen-containing functionalities, most of which may be the donors/acceptors of H-bonds. Several amino acid residues and structural motifs are responsible for BCRP activity and substrate recognition. Thus, the active form of BCRP, at least a dimer or a larger oligomer is maintained by intramolecular disulfide bridge that involves Cys(603) residues. The GXXXG motif in transmembrane helix 1, Cys residues, Arg(482) and Lys(86) are responsible for maintaining the protein structure, which confers transport activity, and the His(457) or Arg(456) residues are directly involved in substrate binding. Arg(482) does not directly bind substrates, but electrostatically interacts with charged molecules, which initiates the conformational changes that transmit the signal from the transmembrane regions to the ABC domain.